Pharmacoeconomic Comparison of Generic and Original-Patented Ceftriaxone Sodium for Injection in the Treatment of Community-Acquired Pneumonia in Children
Objective To compare the pharmacoeconomics of bid-wining Ceftriaxone Sodium for Injection in the National Centralized-Drug Procurement(generic drug)and corresponding original-patented drug in the treatment of community-acquired pneumonia(CAP)in children.Methods A total of 292 children(three months to fourteen years)with non-severe CAP admitted to the Department of Pediatrics in the General Hospital of Xinjiang Military Region from January 2020 to August 2022 were selected by the hospital electronic medical-record system and divided into the group A(140 cases)and group B(152 cases)based on the different therapeutic drugs.The children in the groups A and B were given the intravenous drip of generic and original-patented drug(both with a specification of 1.0 g each)respectively.The clinical efficacy and incidence of adverse reactions in the two groups were obtained,and the treatment costs were calculated.The cost-effectiveness analysis was used to compare the pharmacoeconomics,and the sensitivity analysis was used for verification.Results The effective rates in the groups A and B were similar(87.14%vs.89.47%,P>0.05).The treatment costs(excluding hospitalization costs)in the group A were significantly lower than those in the group B(P<0.01).The time to temperature improvement in the group A was significantly longer than that in the group B,and the incidence of adverse reactions was significantly higher than that in the group B(P<0.05).The incremental cost-effectiveness ratio(ICER)in the group B was 471.36.The sensitivity analysis showed that the ICER in the group B was 424.23 when the total costs decreased by 10%,and that was 364.88 when the effective rate was at the lower limit of the 95%CI.Conclusion The generic Ceftriaxone Sodium for Injection is more economical than original-patented drug.
childcommunity-acquired pneumoniaCeftriaxone Sodium for Injectionoriginal-patented druggeneric drugpharmacoeconomicscost-effectiveness
国家科技期刊平台
NSTL
万方数据
